Search results
May 2, 2024 · Core Illumina revenue of $1.06 billion for Q1 2024, down 2% from Q1 2023 (down 2% on a constant currency basis) Core Illumina GAAP operating margin of 11.0% and non-GAAP operating margin of 20.6% for Q1 2024 Reiterating fiscal year 2024 Core Illumina revenue guidance that is approximately flat compared to 2023 and a Core Illumina non-GAAP operating margin for fiscal year 2024 of approximately ...
An expanding next-generation sequencing (NGS) oncology portfolio is helping Illumina drive the revolution in cancer genomics. Our NGS and microarray technologies are among the most trusted in the world.
Jul 23, 2024 · Illumina Inc. Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Aug 17, 2023 · Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the opening of a new office and state-of-the-art Illumina Solutions Center in Bengaluru, India. Illumina's expansion comes after 16 years of working closely with the company's channel partner in India, Premas Life Sciences. Now with its own permanent facility, Illumina will continue to ...
Jun 26, 2024 · Illumina sequencing and array technologies drive advances in life science research, translational and consumer genomics, and molecular diagnostics.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function.
